CRBU Stock Price, Caribou Biosciences, . Quote, Chart

Market Summary

USD3.87-0.04

Market Closed

-1.02%

CRBU Stock Price

View Fullscreen

CRBU RSI Chart

CRBU Valuation

Market Cap

349.5M

Price/Earnings (Trailing)

-3.42

Price/Sales (Trailing)

10.16

EV/EBITDA

-3.03

Price/Free Cashflow

-3.33

CRBU Price/Sales (Trailing)

CRBU Profitability

EBT Margin

-290.85%

Return on Equity

-23.74%

Return on Assets

-20.67%

Free Cashflow Yield

-30.01%

CRBU Fundamentals

CRBU Revenue

Revenue (TTM)

34.2M

Rev. Growth (Yr)

-3.63%

Rev. Growth (Qtr)

-84.96%

CRBU Earnings

Earnings (TTM)

-94.6M

Earnings Growth (Yr)

-27.85%

Earnings Growth (Qtr)

-244.98%

Breaking Down CRBU Revenue

Last 7 days

-7.9%

Last 30 days

-29.4%

Last 90 days

-24.4%

Trailing 12 Months

-10.4%

How does CRBU drawdown profile look like?

CRBU Financial Health

Current Ratio

14.27

CRBU Investor Care

Shares Dilution (1Y)

44.97%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.7M	0	34.2M	34.4M
2022	10.7M	13.4M	12.7M	13.9M
2021	12.2M	5.2M	8.0M	9.6M
2020	7.4M	9.1M	10.7M	12.4M
2019	0	0	0	5.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Caribou Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 20, 2024	khan ruhi ahmad	acquired	-	-	33,000	chief business officer
Feb 20, 2024	o'byrne jason	acquired	-	-	33,000	chief financial officer
Feb 20, 2024	kanner steven	acquired	-	-	33,000	chief scientific officer
Feb 20, 2024	haurwitz rachel e.	acquired	-	-	118,700	president and ceo
Feb 20, 2024	mcclung barbara g	acquired	-	-	33,000	chief legal officer
Feb 06, 2024	kanner steven	acquired	82,252	2.69	30,577	chief scientific officer
Jun 08, 2023	haurwitz rachel e.	acquired	29,600	2.96	10,000	president and ceo
Mar 20, 2023	haurwitz rachel e.	acquired	29,600	2.96	10,000	president and ceo
Jan 19, 2023	rizvi syed ali-aamir	sold	-35,506	6.31	-5,627	chief medical officer
Dec 02, 2022	kanner steven	acquired	57,568	2.69	21,401	chief scientific officer

Which funds bought or sold CRBU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-29.00	-	-%
Apr 18, 2024	Piscataqua Savings Bank	unchanged	-	-147	1,285	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	9.2	-4,572	219,236	-%
Apr 16, 2024	Thrive Wealth Management, LLC	unchanged	-	-18,880	164,480	0.03%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	122	136,157	273,242	0.01%
Apr 10, 2024	Green Alpha Advisors, LLC	added	4.97	-26,604	429,298	0.31%
Apr 05, 2024	GAMMA Investing LLC	added	291	936	1,347	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	1,900	11,460	0.01%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	55.00	820	1,776	-%

Are Funds Buying or Selling CRBU?

Are funds buying CRBU calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRBU

No. of Funds

Unveiling Caribou Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2024	point72 asset management, l.p.	4.5%	3,958,535	SC 13G
Feb 14, 2024	point72 asset management, l.p.	4.0%	3,521,376	SC 13G/A
Feb 14, 2024	pfm health sciences, lp	7.3%	6	SC 13G/A
Jan 25, 2024	state street corp	5.79%	5,119,666	SC 13G/A
Jan 25, 2024	blackrock inc.	8.0%	7,068,468	SC 13G/A
Jan 08, 2024	avidity partners management lp	7.2%	6,360,212	SC 13G
Jul 20, 2023	point72 asset management, l.p.	4.5%	3,610,739	SC 13G
Jul 10, 2023	pfizer inc	7.1%	4,690,431	SC 13G
Feb 14, 2023	pfm health sciences, lp	7.3%	6	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Caribou Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	8-K	Current Report
Mar 11, 2024	10-K	Annual Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	S-8	Employee Benefits Plan
Feb 23, 2024	SC 13G	Major Ownership Report
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading

Peers (Alternatives to Caribou Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.46	11.9	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.19	3.81	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.33	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Caribou Biosciences, Inc. News

Latest updates

Caribou Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-85.0%	3,558,000	23,662,000	3,502,000	3,692,000	3,303,000	4,192,000	2,664,000	2,559,000	3,977,000	1,476,000	1,586,000	984,000	1,198,000	8,478,000	1,701,000	-
Operating Expenses	7.1%	41,000,000	38,295,000	34,618,000	34,270,000	29,840,000	32,623,000	23,517,000	22,964,000	22,593,000	17,440,000	14,761,000	16,195,000	9,427,000	10,733,000	12,130,000	-
S&GA Expenses	0.1%	9,721,000	9,711,000	8,909,000	8,534,000	9,849,000	10,044,000	9,593,000	7,853,000	6,760,000	5,113,000	4,596,000	4,171,000	3,247,000	3,153,000	3,489,000	-
R&D Expenses	9.4%	31,279,000	28,584,000	25,709,000	25,736,000	19,991,000	22,579,000	13,924,000	15,111,000	15,833,000	12,327,000	10,165,000	12,024,000	6,180,000	7,580,000	8,641,000	-
EBITDA Margin	100.0%	-	-2.81	-6.63	-7.06	-5.13	-4.88	-6.14	-6.84	-7.80	-9.49	-3.05	-2.85	-2.82	-3.33	-	-
Interest Expenses	-	-	-	-	-	-	-	-	1,000	-	2,000	4,000	6,000	6,000	5,000	-	-
Income Taxes	-	23,000	-	-	70,000	-	-	-	315,500	-	-	-	-354,000	-213,000	-50,000	-1,202,000	-
Earnings Before Taxes	-	-	-	-	-45,908,000	-	-	-	-18,158,000	-20,974,000	-14,311,000	-13,159,000	-15,057,000	-8,146,000	-1,922,000	-11,002,000	-
EBT Margin	100.0%	-	-2.91	-6.76	-7.17	-5.24	-4.97	-6.24	-6.94	-7.91	-9.66	-3.13	-2.92	-2.89	-3.41	-	-
Net Income	-245.0%	-34,505,000	-10,002,000	-28,044,000	-26,989,000	-26,647,000	-26,697,000	-19,088,000	-18,479,000	-20,974,000	-14,311,000	-13,159,000	-14,703,000	-7,933,000	-1,872,000	-9,800,000	-
Net Income Margin	100.0%	-	-2.77	-7.38	-7.18	-7.15	-6.36	-6.82	-6.97	-7.87	-9.55	-3.08	-2.78	-2.19	-2.58	-	-
Free Cashflow	100.0%	-	-33,552,000	-29,931,000	-26,801,000	-23,730,000	-24,493,000	-22,396,000	-22,074,000	-15,897,000	-16,960,000	20,291,000	-8,103,000	-8,705,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-5.5%	432	458	350	347	374	399	421	446	442	462	158	36.00
Current Assets	-3.4%	339	351	269	239	260	307	353	368	391	449	143	24.00
Cash Equivalents	-50.8%	51.00	104	66.00	53.00	58.00	82.00	112	148	240	435	130	16.00
Net PPE	10.1%	18.00	17.00	15.00	13.00	11.00	9.00	8.00	6.00	5.00	4.00	4.00	4.00
Liabilities	7.7%	64.00	59.00	80.00	69.00	73.00	75.00	73.00	74.00	55.00	58.00	56.00	18.00
Current Liabilities	15.2%	28.00	25.00	34.00	27.00	28.00	29.00	29.00	27.00	26.00	26.00	26.00	12.00
Shareholder's Equity	-7.5%	368	398	269	278	301	324	348	372	388	404	-	-
Retained Earnings	-13.0%	-299	-264	-254	-225	-197	-170	-143	-116	-97.79	-79.30	-58.34	-30.87
Additional Paid-In Capital	0.5%	668	664	525	504	500	496	493	490	486	484	11.00	7.00
Shares Outstanding	0.0%	88.00	88.00	66.00	61.00	61.00	61.00	61.00	61.00	60.00	46.00	10.00	10.00
Float	-	-	-	263	-	-	-	308	-	-	-	538	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	25.7%	-21,391	-28,776	-15,224	-27,900	-25,044	-22,376	-21,873	-21,673	-21,389	-14,967	-16,476	20,313	-8,076	-8,691	-	-
Share Based Compensation	2.2%	3,556	3,478	3,585	3,131	3,101	2,673	2,918	3,024	1,578	935	593	343	231	248	-	-
Cashflow From Investing	54.0%	-31,474	-68,476	11,064	20,703	1,170	-8,339	-13,973	-72,107	-173,961	-1,930	-484	-22.00	-600	-4.00	-	-
Cashflow From Financing	-100.0%	-43.00	135,128	17,571	1,642	127	654	362	990	460	322,683	606	109,680	82.00	112	-	-

CRBU Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Licensing and collaboration revenue (including $2,393 and $0, from related parties)	$ 34,477	$ 13,851
Operating expenses:
Research and development	112,075	82,230
General and administrative	38,461	38,020
Total operating expenses	150,536	120,250
Loss from operations	(116,059)	(106,399)
Other income (expense):
Change in fair value of equity securities	(6)	(133)
Change in fair value of the MSKCC success payments liability	(1,288)	2,429
Other income, net	15,476	4,752
Total other income	14,182	7,048
Net loss before provision for income taxes	(101,877)	(99,351)
Provision for income taxes	193	70
Net loss	(102,070)	(99,421)
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale marketable securities	1,548	(1,383)
Net comprehensive loss	$ (100,522)	$ (100,804)
Net loss per share, basic (in dollars per share)	$ (1.38)	$ (1.64)
Net loss per share, diluted (in dollars per share)	$ (1.38)	$ (1.64)
Weighted average common shares outstanding, basic (in shares)	73,807,597	60,801,133
Weighted average common shares outstanding, diluted (in shares)	73,807,597	60,801,133

CRBU Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 51,162	$ 58,338
Marketable securities, short-term	277,665	189,325
Accounts receivable	148	202
Contract assets	1,425	2,247
Other receivables	2,286	2,215
Prepaid expenses and other current assets	6,155	7,921
Total current assets	338,841	260,248
NON-CURRENT ASSETS
Investments in equity securities	7,753	7,698
Marketable securities, long-term	43,577	69,373
Property and equipment, net	18,270	10,678
Operating lease, right of use assets	22,182	24,230
Other assets	1,586	1,538
TOTAL ASSETS	432,209	373,765
CURRENT LIABILITIES:
Accounts payable	3,120	1,146
Accrued expenses and other current liabilities	21,135	16,079
Operating lease liabilities, current	1,200	966
Deferred revenue ($2,487 and $150 from related party, respectively)	2,847	9,937
Total current liabilities	28,302	28,128
LONG-TERM LIABILITIES
Deferred revenue, net of current portion ($3,730 and $0 from related party, respectively)	6,102	15,954
MSKCC success payments liability	2,939	1,651
Operating lease liabilities, non-current	25,908	26,780
Deferred tax liabilities	557	381
Total liabilities	63,808	72,894
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS’ EQUITY
Common stock, par value $0.0001 per share, 300,000,000 shares authorized at December 31, 2023 and 2022, respectively; 88,448,948 and 61,029,184 shares issued and outstanding at December 31, 2023 and 2022, respectively	8	6
Additional paid-in-capital	667,648	499,598
Accumulated other comprehensive income (loss)	30	(1,518)
Accumulated deficit	(299,285)	(197,215)
Total stockholders’ equity	368,401	300,871
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 432,209	$ 373,765

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

CEO	Dr. Rachel E. Haurwitz Ph.D.
WEBSITE	https://cariboubio.com
INDUSTRY	Biotechnology
EMPLOYEES	137

Caribou Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Caribou Biosciences, Inc.? What does CRBU stand for in stocks?

CRBU is the stock ticker symbol of Caribou Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Caribou Biosciences, Inc. (CRBU)?

As of Fri Apr 19 2024, market cap of Caribou Biosciences, Inc. is 349.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBU stock?

You can check CRBU's fair value in chart for subscribers.

What is the fair value of CRBU stock?

You can check CRBU's fair value in chart for subscribers. The fair value of Caribou Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Caribou Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRBU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Caribou Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether CRBU is over valued or under valued. Whether Caribou Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Caribou Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBU.

What is Caribou Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CRBU's PE ratio (Price to Earnings) is -3.42 and Price to Sales (PS) ratio is 10.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBU PE ratio will change depending on the future growth rate expectations of investors.